Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Crohn's Disease in Remission Clear all
Completed Phase 3 Interventional

An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease

NCT00074542
View directory record Official record
Conditions
Crohn's Disease
Interventions
Epanova™ (Omega-3 Free Fatty Acids)
Drug
Lead sponsor
Tillotts Pharma AG
Industry
Eligibility
16 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • Urbana, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2007 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional

Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease

NCT00543374
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, PROCHYMAL adult human mesenchymal stem cells
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
53
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 3, 2026, 7:32 PM EDT
Terminated Early Phase 1 Interventional

Maintenance Dosing of Vitamin D in Crohn's Disease

NCT03615378
View directory record Official record
Conditions
Crohns Disease, Vitamin D Deficiency
Interventions
5000 IU D3, 1000 IU D3, Placebo
Dietary Supplement
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 3, 2026, 7:32 PM EDT
Recruiting Not applicable Interventional

A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease

NCT05849012
View directory record Official record
Conditions
Crohn's Disease in Remission
Interventions
Low Sulfur Diet, Usual Diet
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Not applicable Interventional Results available

Crohn Disease Exclusion Diet After Single Medication De-escalation

NCT02472457
View directory record Official record
Conditions
Crohn Disease
Interventions
Crohn Disease Exclusion Diet, Free Diet
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

NCT03009396
View directory record Official record
Conditions
Crohn Disease
Interventions
RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 76 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
San Carlos, California • Marietta, Georgia • Topeka, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 3, 2026, 7:32 PM EDT
Terminated Phase 2 Interventional Results available

Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

NCT04186247
View directory record Official record
Conditions
Crohn Disease, Pediatric Crohns Disease
Interventions
Azithromycin, Metronidazole, Standard of Care
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

NCT00783692
View directory record Official record
Conditions
Crohn's Disease
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
110
States / cities
Birmingham, Alabama • Los Angeles, California • Montebello, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 3, 2026, 7:32 PM EDT
Not listed No phase listed Observational

Microbial and Human Determinants of the Onset of IBD Flares

NCT05463900
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated, Crohn Disease in Remission
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional

Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease

NCT00056355
View directory record Official record
Conditions
Crohn Disease
Interventions
UVADEX and UVAR XTS Photopheresis System
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional

Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease

NCT00944736
View directory record Official record
Conditions
Crohn's Disease
Interventions
VSL#3, Placebo
Dietary Supplement
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
11 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 3, 2026, 7:32 PM EDT
Terminated Phase 3 Interventional Results available

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

NCT02240108
View directory record Official record
Conditions
Crohn's Disease
Interventions
Rifaximin EIR, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
78
States / cities
Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 2 Interventional

A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

NCT00055523
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab (D2E7)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
43
States / cities
Berkeley, California • Long Beach, California • San Diego, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2006 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 4 Interventional

Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy

NCT01698307
View directory record Official record
Conditions
Crohn's Disease
Interventions
Enhanced Treatment Algorithm, Conventional Step-care Algorithm
Other
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Urbana, Illinois • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 3, 2026, 7:32 PM EDT
Terminated Phase 3 Interventional

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

NCT00295165
View directory record Official record
Conditions
Crohn Disease
Interventions
Sargramostim (Leukine), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
47
States / cities
Huntsville, Alabama • Orange, California • San Francisco, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

NCT02914561
View directory record Official record
Conditions
Crohn's Disease
Interventions
Filgotinib, Placebo
Drug · Other
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
101
States / cities
Dothan, Alabama • Sun City, Arizona • Coronado, California + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 3, 2026, 7:32 PM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Crohn's Disease

NCT04100005
View directory record Official record
Conditions
Crohn Disease, Crohn Colitis, Crohn's Ileocolitis, Crohn Ileitis, Crohn Disease of Ileum, Crohn's Disease Relapse, Crohn's Gastritis, Crohns Disease Aggravated, Crohn Disease in Remission, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Disease of Pylorus, Crohn's Esophagitis, Crohn's
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 1 Interventional

Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose

NCT00868660
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
ZP1848
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 3, 2026, 7:32 PM EDT
Recruiting Not applicable Interventional

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

NCT05230173
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease
Interventions
Pragmatic
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

NCT00552058
View directory record Official record
Conditions
Crohn Disease
Interventions
certolizumab pegol (CDP870, CZP), Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Pell City, Alabama • Colorado Springs, Colorado • Lakewood, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

NCT00055536
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 3, 2026, 7:32 PM EDT
Recruiting Phase 2Phase 3 Interventional

Precise Infliximab Exposure and Pharmacodynamic Control

NCT05660746
View directory record Official record
Conditions
Crohn Disease
Interventions
RoadMAB, Infliximab
Device · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 22 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 3, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Remission in Subjects With Crohn's Disease, 1 Year Phase

NCT00055497
View directory record Official record
Conditions
Crohn's Disease
Interventions
Double-blind (DB) adalimumab placebo, DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
43
States / cities
Berkeley, California • Long Beach, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 3, 2026, 7:32 PM EDT
Terminated Phase 3 Interventional Results available

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

NCT01316939
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Little Rock, Arizona • Tucson, Arizona • La Jolla, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 3, 2026, 7:32 PM EDT